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Abstract  
The putative resident stem or progenitor cells have been identified in bronchioalveolar duct 
junction (BADJ) of mice lung. However, contribution of this stem cell expressing both CCSP 
and SP-C in maintenance of normal homeostasis and repair after lung injury is still unclear. In 
this study, I identified CCSP
pos
/SP-C
pos 
epithelial cells in the BADJ by dual 
immunofluorescence, and then quantified CD45
neg
/CCSP
pos
/SP-C
pos 
cells in normal and 
injured lung. The CCSP
pos
/SP-C
pos 
epithelial cells in the BADJ were identified as a single cell 
from embryo 18 days to 7 months after birth. The percentage of CD45
neg
/CCSP
pos
/SP-C
pos 
cells was between 0.48% ± 0.05% and 1.11% ± 0.10% and relatively stable up to 7 months. 
When mice lung tissues were treated with naphthalene, the proliferation of CCSP
pos
/SP-C
pos 
cells was observed as patches of this double positive cells and preceded the recovery of 
bronchioles. In contrast, when the lung was treated by bleomycin, although the proliferation 
of CCSP
pos
/SP-C
pos cells was observed but later than recovery of alveolar type II epithelial 
cells. My results suggest that the CD45
neg
/CCSP
pos
/SP-C
pos 
progenitor cells in the BADJ 
mainly regenerate bronchiolar epithelial cells but not alveolar epithelial cells. 
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Introduction  
Multicellular organisms must generate new cells to maintain the structure and function of 
their tissues. It is currently believed that this ability is derived from resident stem or 
progenitor cells that have self-renewal capacity and differentiation capacity to special 
functional cell types in the specific organs (1). The lung possesses a complex architecture 
with multiple cell types including bronchial and alveolar epithelial cells, interstitial fibroblasts, 
and pulmonary endothelial cells. These complex structures and unique function of gas 
exchange cause difficulties in analyzing turnover of lung cells. Lung tissues can be repeatedly 
damaged by various oxidants, air-pollutants, infectious organisms, and others. Therefore, 
epithelial cells in the lung must be repaired after these injuries. Chronic injuries and 
incomplete or inappropriate repair lead to development of lung diseases such as chronic 
obstructive pulmonary disease, idiopathic pulmonary fibrosis, and lung cancer. 
In adult rat, lung epithelial cells undergo slow homeostatic turnover resulting in a 
replacement of epithelial cells after approximately four months (2). Both homeostatic 
turnover and regeneration after injury lead to an idea of presence of endogenous stem or 
progenitor cells in the lung. However, the identity of the resident stem or progenitor cells 
responsible for lung growth, homeostasis, and repair remains poorly characterized.   
A composition of the lung epithelium varies along the regions (trachea, bronchioles, and 
alveoli). Previous studies suggested candidates of resident stem or progenitor cells in different 
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regions, basal cells in the trachea (3,4), Clara cells in the bronchioles (5), and type II cells in 
the alveoli (6, 7). Following naphthalene injury, Clara cell population is restored only by the 
self-renewal of a resistant or variant Clara cells located near the neuroendocrine bodies (NEB) 
in the terminal bronchioles and bronchioalveolar duct junction (BADJ) (8,9). Recently, cells 
co-expressing Clara cell secretory protein (CCSP), a marker for Clara cells, and 
pro-surfactant-C protein (SP-C), a specific marker for type II alveolar cells have been 
identified as bronchioalveolar stem cells (BASC) which locates in unique region called BADJ 
at the terminal ends of distal bronchioles (10). These BASCs are resistant to lung injury by 
naphthalene and proliferate after these injuries. Cultured BASCs exhibit proliferative capacity 
and self-renewal and are multipotency in clonal assays. But the characteristics of BASCs in 
vivo are still unclear.  
In this study, I analyzed changes of lung progenitor cells co-expressing CCSP and SP-C in 
the BADJ during lung development, growth, and repair after injury by immunofluorescence 
on the lung tissue sections. I also established a method of quantification of lung progenitor 
cell numbers by flow cytometry. Number of this cell population was analyzed during lung 
growth, injury and repair.  
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Materials and Methods 
Animal Husbandry 
All animal experiments were conducted in accordance with the Animal Research Ethics 
Committee in Hirosaki University Graduate School of Medicine and followed the Guidelines 
for Animal Experimentation of Hirosaki University. Female C57BL/6N mice, 4 weeks ~ 7 
months of age, were purchased from CLEA Japan Inc. (Tokyo, Japan). Mice were 
maintained in the Hirosaki University Graduate School of Medicine Animal Care Service 
Facility under a cycle of 12 hours light (50 lux illumination in the cage) and 12 hours dark 
(<10 lux of environmental illumination). For fetal and newborn mice experiments, mice were 
mated during the night, and the day of the discovery of the vaginal plug was counted as 
embryonic day 0. Experiments were performed on mice pups at embryonic 12, 14, 16, 18 
days, newborn, 4 days, 1 and 2 weeks old. 
Lung injury models 
8 weeks old mice were used for lung injury experiments. For bronchiolar epithelium injury, 
naphthalene (> 99% pure) was dissolved as 20 mg/ml in corn oil (both from Wako Co., Ltd., 
Tokyo, Japan) and administered via a single intraperitoneal as a dose of 200 mg/kg body 
weight. Mice were sacrificed at different times (24, 48, 96 hours and 1, 2, 4, 6 weeks) after 
treatment with naphthalene or corn oil. All mice experiment procedures were performed 
between 10:00 AM and 11:30 AM to minimize influence of diurnal glutathione abundance 
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fluctuations on extent of naphthalene injury. 
For alveolar epithelium injury, the mice were administered 6.6 U/kg bleomycin (Sigma 
Chemical Co., St Louis, MO, USA) dissolved in saline in a total volume of 100 µl by 
intratracheal instillation. Mice were sacrificed at same times as naphthalene experiments after 
treatment with bleomycin. All mice experiment procedures were performed between 
10:00 AM and 11:30 AM. 
Immunohistochemistry 
Mouse lung tissues were cut to desired shapes, keeping the thicknesses no more than 3mm, 
than fixed in 10% buffered formalin for 24 hours. Five-micrometer thick lung sections were 
stained with haematoxylin and eosin (H&E) for histological examination. For 
immunohistochemical staining, goat anti-mouse CCSP (1:500; sc-9772, Santa Cruz 
Biotechnology, Santa Cruz, CA) and rabbit anti-mouse SP-C (1:500; AB3786, Millipore, 
Billerica, MA) were used as primary antibody. Goat IgG and rabbit IgG were used as isotype 
control. The lung sections were deparaffinized by successive incubation in xylene and ethanol 
by standard procedures. Retrieval of antigens was performed by incubating the sections in 
antigen retrieval solution (415211, Nichirei, Tokyo Japan) at 120°C for 10 minutes in an 
autoclave. After the endogenous peroxidase activity was blocked with Peroxidase Blocking 
Reagent (S2001, Dako), the tissue sections were washed three times in PBS and blocked with 
Protein Block Serum-Free (X0909, Dako) for 20 minutes at room temperature. After blocking, 
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sections were incubated with primary antibody for 1 hour at room temperature and washed. 
Sections were then incubated with the appropriate secondary antibody with a peroxidase 
conjugate for 30 minutes at room temperature, and then incubated with AEC. 
Immunofluorescence 
For paraffin sections, specimens were deparaffinized and retrieved as described above. The 
sections were incubated with primary antibody goat anti-mouse CCSP (1:500) and rabbit 
anti-mouse SP-C (1:500, Millipore) together at 4°C overnight. Goat IgG and rabbit IgG were 
used as isotype control. After washing three times with PBS, sections were incubated with 
secondary antibody donkey anti-goat IgG-Alexa 594 (1:200; A11058, Invitrogen, Carlsbad, 
CA,) and donkey anti-rabbit IgG-Alexa 488 (1:200; A21206, Invitrogen). For double staining 
of Ki-67 and CCSP or SP-C, the sections were incubated with primary antibodies rabbit 
anti-mouse Ki-67 (1:200; ab15580, Abcom, Cambridge, UK) and goat anti-mouse CCSP 
(1:500) or goat anti-mouse SP-C (1:100; sc-7706, Santa Cruz Biotechnology). Donkey anti 
rabbit IgG-Alexa 488 and donkey anti-goat IgG-Alexa 594 were used as secondary antibodies. 
For frozen sections, the lung tissues were fixed with 4% paraformaldehyde and 12%, 15%, 
18% sucrose buffer by steps over 12 hours, then embedded by OCT. Five-micrometer thick 
frozen sections were stained by primary antibody goat anti-CCSP (1:500) and rat anti-CD45 
(1:100; 550539, BD San Jose, CA) or rabbit anti-SP-C (1:500, Millipore) and rat anti-CD45 
(1:100) double staining. Goat IgG, rabbit IgG and rat IgG2a were used as isotype control. 
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Secondary antibodies were donkey anti-goat IgG-Alexa 488(1:200; A11055, Invitrogen) or 
donkey anti-rabbit IgG-Alexa 488 and donkey anti-rat IgG-Alexa 594 (1:200; A21209, 
Invitrogen) respectively. For triple staining of Sca-1, CCSP and SP-C, the sections were 
incubated with primary antibodies biotin-conjugated Sca-1 (1:100; 553334, BD, San Jose, 
CA), goat anti-mouse CCSP (1:500) and rabbit anti-mouse SP-C (1:500; Millipore), and 
AMCA avidin D (1:100; A-2008, VECTOR, Burlingame, CA), donkey anti-goat IgG-Alexa 
594 and donkey anti rabbit IgG-Alexa 488 were used as secondary antibodies. 
Flow Cytometry 
Single-cell suspensions from the mice lungs were prepared as described by CRLRA KIM 
LAB (http://kim.tchlab.org/). Briefly, anesthetized mice with avertin were cut into rib cage, 
cut a slit in left ventricle, and perfused 50 ml of PBS (ice cold) through right ventricle until 
lungs cleared of blood. Then, dispase solution (BD) was injected into trachea just until the 
lungs inflate, followed with tracheal injection of 0.5 - 1 ml of 1% LMP agarose (in H2O). 
Finally lung tissues were minced into small pieces. Each lung sample were added 6 ml PBS 
and 120 µl collagenase/dispase solution (Roche Diagnostics, Mannheim, Germany), rotated 
45 minutes at 37°C, filtered through a 100 µm filter and 40 µm filter. Cells were resuspended 
in lysing solution (Gibco, Grand Island, NY) for complete red blood cell lyses. Isolated cells 
were fixed and permeabilized for intracellular antigens by incubating for 10 minutes at 4°C in 
1% paraformaldehyde (Wako) in PBS and then 20 minutes at 4°C in 0.1% saponin (Sigma) in 
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PBS. After that cells were resuspended at 1 × 10
7
 cells in 90 µl of PBS including 1 mM EDTA 
and 3% fetal bovine serum (FACS buffer) and incubated with 10 µl Mouse FcR Blocking 
Reagent (130-092-575, MACS, Auburn, CA) at 4°C for 10 minutes and washed with 1 ml 
FACS buffer. The cells were incubated with the indicated antibodies for 20 minutes on ice. 
Antibodies used were goat anti-mouse CCSP (1:25), rabbit anti-mouse SP-C (1:50, Millipore), 
biotined rat anti-mouse CD45 (1:50; 732149, Beckman Coulter, Fullerton, CA). The goat IgG, 
rabbit IgG, and rat IgG 2a were used as isotype control. The cells were incubated with 
secondary antibodies for 10 minutes at room temperature in dark. Secondary antibodies used 
were swine anti-goat IgG-PE, donkey anti-rabbit IgG-FITC, Streptavidin-PC5 (IM3327, 
Beckman coulter, Fullerton, CA). Finally, the cells were analyzed by a FACS-Cell Lab Quanta 
SC (Beckman Coulter, http://www.beckmancoulter.co.jp).  
Magnetic associated cell sorting  
Single-cell suspensions were performed using the above protocol from 8 weeks old mice 
lungs. After FcR-blocking according to the manufacturer's instructions (Miltenyi Biotec, 
Auburn CA), single cells were labeled with rat anti-mouse CD45-MicroBeads (10 µl per 1 × 
10
7
 cells; 130-052-301, Miltenyi Biotec) for 20 minutes at 4°C. Magnetic separation with LS 
column was performed according to the manufacturer's instructions and unlabeled cells (i.e. 
CD45
neg
 cells) which pass through the column were collected. Homogeneity of isolated 
CD45
neg
 lung cells was analyzed by flow cytometry using rat anti-mouse CD45-FITC-labeled 
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antibodies (1:50; 553079, BD) or the appropriate FITC-labeled isotype control antibodies. 
After that, isolated cells else were analyzed by flow cytometry using rat anti-mouse 
Sca-1-biotin (1:50; 130-093-421, Miltenyi Biotec) antibody or the appropriate biotined 
isotype control antibodies.  
Statistical Analysis 
The results were expressed as mean ± SD. Statistical comparison was made using the 
Tukey-Kramer method, and a value of p < 0.05 or p < 0.01 was accepted as indicating 
significance. 
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Results  
CCSP
pos
/SP-C
pos 
lung epithelial cells in bronchioalveolar duct junction (BADJ) 
To determine whether CD45, common leukocyte antigen, a marker for hematopoietic stem 
cells, is expressed on the surface of lung epithelial cells, I examined the lung frozen sections 
of 8 weeks old mice by dual immunofluorescence for CD45 and CCSP, or CD45 and SP-C 
respectively. As shown in Figure. 1A, although CCSP
pos
 Clara cells and SP-C
pos
 alveolar type 
II cells were identified at the bronchus and alveoli, neither of CCSP
pos
 cells nor SP-C
pos
 cells 
expressed CD45. This result indicated CCSP and SP-C are expressed in CD45
neg 
lung cells. 
Next, I identified CCSP
pos
/SP-C
pos 
epithelial cells at bronchioalveolar duct junction (BADJ) of 
the lung in 8 weeks old mice by dual immunofluorescence in paraffin sections as Figure. 1B. I 
defined CD45
neg
/CCSP
pos
/SP-C
pos
 cells as lung progenitor cells. Although I also identified 
CCSP
pos
/SP-C
pos
/Sca-1 
pos 
epithelial cells in BADJ (Figure. 2A), a study reported that Sca-1 
immunoreactivity does not distinguish between bronchiolar stem and facultative transit 
amplifying cell populations (11) and Sca-1 positive cell fraction enriched endogenous 
fibroblast progenitor cells in adult lung (12). In my study, contrary to the proliferation of 
CD45
neg
/CCSP
pos
/SP-C
pos
 cells (Figure. 3D), the percentages of CD45
neg
/Sca-1 
pos 
lung cells 
indeed increased in accordance with aging (Figure. 2B). Therefore, Sca-1 had been in 
abeyance in this study.  
Changes of CD45
neg
/CCSP
pos
/SP-C
pos 
lung progenitor cells during lung development, growth 
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and aging 
Mice lung tissues were collected from embryo 12 days until 7 months old. Paraffin sections 
were stained by dual immunofluorescence as shown in Figure. 3A. At embryo 12 days neither 
SP-C protein nor CCSP protein was expressed on the lung cells. At embryo 14 days, SP-C 
protein started to be expressed from embryo 14 days, whereas CCSP protein started from 16 
days. Although both of CCSP and SP-C protein were expressed in lung cells on embryo 16 
days, double positive lung cells were not identified. At embryo 18 days when the structures of 
alveoli and bronchi have been discerned, CCSP
pos
/SP-C
pos 
lung cells were identified. After 
birth, CCSP
pos
/SP-C
pos 
lung cells were identified in the BADJ at whole time points during 
growth and aging. Single positive cells, CCSP
pos 
or SP-C
pos 
cells, appeared earlier than CCSP
 
SP-C
 
double positive lung cells during fetal development.  
To quantify the percentage of CD45
neg
/CCSP
pos
/SP-C
pos 
cells in whole lung cells during 
development, growth and aging, single lung cell suspensions were prepared at different time 
points. The protocol provided by Carla Kim Lab for preparing single lung cells could be 
improved for isolation of alveolar type II cells and BACS, but may limit the number of Clara 
or other bronchiolar cells. Despite some lung cells may be lost in the process, the proportions 
of losing cells in each experiment were probably the same, so I think the final results at 
different time points can be compared. As shown in Figure. 3B bottom, the lung tissues were 
cleared of blood, but it was difficult to completely remove. So I regard the single lung cell 
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suspensions as total lung cells including lung epithelial cells, lung fibroblasts, pulmonary 
endothelial cells, immune cells and few blood cells. The number of total lung cells increased 
during growth, but did not change during aging or after lung injury by statistical analysis 
(Figures. 3C, 4H and 5J). The percentages of CD45
neg
/CCSP
pos
/SP-C
pos 
cells in total lung cells 
were validated by 4-6 times repeated experiments. As stated above, both CCSP and SP-C 
proteins are expressed in CD45
neg 
lung cells, the percentages of CD45
neg
/CCSP
pos
/SP-C
pos
 
cells were counted as lung progenitor cells in total lung cells, and the co-expression of goat 
IgG and rabbit IgG in CD45
neg 
lung cells were counted as isotype control (Figure. 3B). The 
results are shown in Figures. 3D and 3G.. The percentages of CD45
neg
/CCSP
pos
/SP-C
pos 
lung 
progenitor cells increased from 0.81% ± 0.04% on embryo 17-18 days to 1.11% ± 0.10% at 4 
days, gradually declined to 0.52% ± 0.04% at 4 weeks, and kept plateau during aging. The 
percentages of this cell subpopulation were only under 1.2% during whole time points (Figure. 
3D). The resulting numbers of CD45
neg
/CCSP
 neg
/SP-C
pos
 lung cells increased and peaked at 4 
days after birth as the highest level of 3.84% ± 0.58%, and then gradually declined until 7 
months (Figure. 3F). Similarly, the resulting percentages of CD45
neg
/CCSP
pos
/SP-C
neg 
lung 
cells increased and reached as the highest level 3.44% ± 0.72% at 1 week and gradually 
declined until 7 months (Figure. 3E).  
Changes of CD45
neg
/CCSP
pos
/SP-C
pos 
lung progenitor cells after lung injury by naphthalene 
To observe the dynamic changes of CD45
neg
/CCSP
pos
/SP-C
pos
 lung progenitor cells following 
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Clara cell-specific depletion, 8 weeks old adult female mice were treated with naphthalene. 
The time course of naphthalene-induced Clara cell injury and
 
repair defined by AEC staining 
was consistent with previous studies (Figure. 4A) (13, 14). This prominent histopathological 
change was detected at 48 hours after injection with naphthalene. The necrotic cells left from 
bronchiolar epithelium, the basement membrane became denuded with only few uninjured 
and flattened bronchiolar epithelial cells remaining intact. No histopathological change in 
bronchial epithelium was observed on treatment group with corn oil only (data not shown). As 
shown in Figure. 4B, double immunofluorescence staining for Ki-67 and CCSP were used to 
determine Clara cell proliferation in the bronchiolar epithelium after injury. In the bronchiolar 
epithelium, a low baseline level of Ki-67 positive cells was observed in control mice (Figure. 
4B) and after corn oil injection (data not shown). At 48 hours after naphthalene injection, the 
number of Ki-67
pos
/CCSP
pos
 cells increased until 2 weeks after treatment and then decreased 
to control level by obersving the double immunofluorescence staining images. I also observed 
the CCSP
pos 
cells were injured and disappeared after naphthalene treatment from 24 hours to 
96 hours, but these CCSP
pos
 cells recovered after 1 week (Figure. 4A). During this bronchiolar 
epithelial recovery, the proliferative response of CCSP
pos
/SP-C
pos
 lung progenitor cells was 
observed as patches of double positive cell identified in BADJ since 96 hours to 4 weeks after 
treatment (Figure. 4C). The bronchiolar epithelium voluminously regenerated and restored 
with abundance of Clara cells by 6 weeks after treatment. The numbers of total lung cells for 
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flow cytometry analysis at different time points were not changed after lung injury(Figure. 
4H), and the percentages of cell subpopulation in total lung cells were compared by 
quantitative analysis. The nadir of mean survival Clara cells was detected at 96 hours with the 
percentage of 0.80% ± 0.05% and returned to baseline level by 4 - 6 weeks after treatment 
(Figure. 4E). The mean score of CD45
neg
/CCSP
pos
/SP-C
pos
 lung progenitor cells were not 
reduced after naphthalene-induced lung injury, indicating lung progenitor cells were resistant 
to naphthalene injury. The percentage of CD45
neg
/CCSP
pos
/SP-C
pos
 cells peaked at 1 week 
(0.75% ± 0.06%) after treatment and thereafter declined (Figure. 4D). The peak of 
CD45
neg
/CCSP
pos
/SP-C
pos
 cells preceded an increasing CD45
neg
/CCSP
pos
/SP-C
neg 
cells (Figure. 
4G). 
CD45
neg
/CCSP
pos
/SP-C
pos 
lung progenitor cells after lung injury by Bleomycin 
Lung inflammation, excessive weight loss, and mortality by intratracheal injection of 
bleomycin were defined as previously described (15, 16) (Figures. 5A and 5B). The reduced 
number of SP-C
pos 
alveolar type II cells was observed from 24 hours, bottom out at 96 hours, 
but did not returned to baseline level before the whole 6 weeks experiment (Figures. 5C, 5D 
and 5H). Double immunofluorescence staining for Ki-67 and SP-C was used to determine cell 
proliferation. A low level of Ki-67 positive cells was observed in control mice (Figure. 5D) or 
after saline injection (data not shown). I observed that Ki-67
pos
 cells were increased in the 
both SP-C positive or negative cells in alveoli after 96 hours, and the Ki-67
pos
 cells detected in 
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the fibrotic foci after 2 weeks, suggesting these Ki-67
pos
 cells were fibroblasts, endothelial cell, 
or inflammatory cells (Figure. 5D insets). Quantitative analysis also showed the percentage of 
CD45
neg
/CCSP
neg
/SP-C 
pos
 cells drop nadir on 96 hours as the lowest level of 1.23% ± 0.07% 
and then started to recover, but never reached baseline level (Figure. 5H). A proliferative 
response of CCSP
pos
/SP-C
pos
 lung progenitor cells was observed as double positive cell patch 
identified at BADJ from 2 weeks to 4 weeks after treatment (Figure. 5E). However, 
comparing with naphthalene treatment, the increase of CD45
neg
/CCSP
pos
/SP-C
pos 
lung 
progenitor cells by bleomycin treatment was not significant and later than naphthalene 
treatment (Figures. 4D and 5F). These results suggested the CD45
neg
/CCSP
pos
/SP-C
pos 
lung 
progenitor cells might not be the source of SP-C
pos 
alveolar type II cells or at least not the 
main source. Or, the lung alveolar epithelial cells could not appropriately regenerate after 
bleomycin injury. Interestingly, the percentage of CCSP
pos 
Clara cells gradually declined from 
24 hours to 2 weeks after treatment, but unexpectedly the CCSP
pos 
Clara cells grew fast from 
2 weeks and exceeded the baseline level (Figure. 5G). The proliferation of bronchiolar 
epithelium at 6 weeks was also identified by immunostaining of Ki-67 (Figure. 5D the last 
picture). Immunohistochemistry of CCSP demonstrated CCSP positive cells presented not 
only bronchioles but also in the alveolar structures where CCSP
pos 
Clara cells do not exist at 
normal status (Figure. 5K). I suggest that bleomycin-induced lung injury leaded to abnormal 
epithelial morphology and proliferation, named alveolar bronchiolization (17, 18).   
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Discussion  
In this study, I identified that lung progenitor cells co-expressing CCSP and SP-C appeared at 
embryo 18 days when the bronchiole and alveoli discerned and did exist in the 
bronchioalveolar duct junction (BADJ) until 7 months. I have developed a method of 
quantification of CD45
neg
/CCSP
pos
/SP-C
pos
 cells by flow cytometry. Unfortunately, I have not 
rule out the impact of residual blood cells in total lung cells on the result. It is necessary to 
evaluate the effect of blood-removal treatment, in my opinion, lymphocyte maker CD2 (one 
common marker of  T cells, B cells and NK cells) and red blood cell marker Ter-119 can be 
used respectively by flow cytometry to confirm the percentages of residual lymphocyte and 
red blood cells in total lung cells. Furthermore, according to the data that lymphocytes usually 
account for 86.4% ± 3.44% of white blood cells in the circulation of female adult C57BL/6N 
mouse, the percentage of residual white blood cells can be inferred. 
Quantification of lung progenitor cells shows that CD45
neg
/CCSP
pos
/SP-C
pos
cell 
population increases after birth and decline but maintain steady level until 7 months. 
Proliferation of CD45
neg
/CCSP
pos
/SP-C
pos
cell after naphthalene treatment suggests this 
population contribute a repair of bronchioles. However, CD45
neg
/CCSP
pos
/SP-C
pos
cell could 
not contribute regeneration of alveoli by bleomycin-induced injury. 
During embryonic development, I identified that SP-C expressing cells in the alveolar-like 
structure on embryo 14 days and CCSP expressing epithelial cells in bronchus-like structure 
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on embryo 16 days. The cells co-expressing CCSP and SP-C for the first time appeared on 
embryo 18 days. Therefore, I suggest that the CCSP
pos
/SP-C
pos
 lung cells could not be a 
source of CCSP
pos
 Clara cells or SP-C
pos
 alveolar type II epithelial cells in the embryo stage. 
In the contrary, a previous study reported that calcitonin gene related peptide (CGRP), Clara 
cell 10-KD protein (same as CCSP) and surfactant protein A (SP-A) are co-expressed in most 
or all epithelium of distal airways during early embryonic lung development (embryo 13 – 15 
days) and later become restricted to different cell lineages (19). This study was on the basis of 
immunohistochemical staining which I have also done (data not shown). I found the real 
positive cells were hard to be identified because of presence of false positive cells during 
early embryonic development. Therefore, I considered that my results are more reliable. 
After birth to 7 months, progenitor cells exist in only BADJ and have never discovered in 
other places as previously reported (10). Therefore, I assumed that CCSP
pos
/SP-C
pos
 cells 
are lung progenitor cells. In the quantitative analysis of the CD45
neg
/CCSP
pos
/SP-C
pos
 lung 
progenitor cells during growth and aging, although CD45
neg
/CCSP
pos
/SP-C
pos
 lung progenitor 
cells are relatively stable, this cell population increase up to 4 days, decline thereafter and 
became steady status. The CD45
neg
/CCSP
neg
/SP-C
pos
 alveolar type II epithelial cells showed 
similar changes as progenitor cells. On the other hand, CD45
neg
/CCSP
pos
/SP-C
neg
 Clara cells 
were slightly behind those. I could assume that at least during the growth 
CD45
neg
/CCSP
pos
/SP-C
 pos
 lung progenitor cells can be a source for Clara cells but not 
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alveolar type II epithelial cells. 
The results of lung injury model by naphthalene or bleomycin are different with findings of 
normal development and growth. The CD45
neg
/CCSP
pos
/SP-C
pos
 lung progenitor cells are 
resistant to both naphthalene and bleomycin, suggesting this cell population has 
characteristics for stem cells. I have observed that progenitor cells developed irregular patches 
1-2 weeks after naphthalene injection by immunofluorescence. FACS analyses also indicate 
that the level of CD45
neg
/CCSP
pos
/SP-C
pos
 lung cells increased after naphthalene injury before 
increasing number of CD45
neg
/CCSP
pos
/SP-C
neg
 Clara cells. However, magnitude of 
progenitor cells proliferation is small and later than recovery of CD45
neg
/CCSP
neg
/SP-C
pos
 
alveolar type II epithelial cells after bleomycin treatment. Therefore, I assume that progenitor 
cells can be major source of Clara cells in the bronchiole but not of alveolar type II epithelial 
cells after lung injury. Similarly, Giangreco A et al have reported that single, randomly 
distributed progenitor cells maintain normal epithelial homeostasis, and that BADJ associated 
stem cells only restore airways after severe lung injury by naphthalene (20). Rawlins et al also 
demonstrated lineage-tracing CCSP expressing cells self-renew and generate ciliated cells, 
and thus maintain the normal airway epithelium. They find no evidence of contribution of 
BASC during postnatal growth, homeostasis, or repair (21).   
There has been only one report that quantitative analysis of stem cells in the lung was 
performed (22). In that study, they defined BASCs were double-stained with CCSP and 
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proSP-C same as I determined. Quantitative analysis using a system biology model was used 
to evaluate the potential contribution of BASCs and alveolar type II epithelial cells. BASCs 
contribute only between 0% - 25% of alveolar epithelial regrowth after pneumonectomy, 
suggesting substantial contribution of alveolar type II epithelial cells. Together with my 
results, stem cells in BADJ could contribute only small part for regrowth of alveolar 
epithelium. 
I found interesting phenomenon of alveolar bronchiolization after bleomycin injury (18). 
The images of AEC staining showed the proliferation of Clara cells even in alveolar ducts at 6 
weeks. Preceded proliferation of CD45
neg
/CCSP
pos
/SP-C
neg
 Clara cells in 4-6 weeks suggested 
this bronchiolization was due to inappropriate proliferation of lung progenitor cells.  
For the proliferation of Clara cells and alveolar type II epithelial cells during lung injury 
and repair, I just observed by morphological staining. Although I can find out the changes in 
the number of proliferating cells in the BADJ roughly. But it is not enough to identify the 
change of overall Clara cell and alveolar type II epithelial cells in lung tissues. The 
proliferation could be confirmed more appropriately by quantitative analysis of two-color 
flow cytometry for Ki67
pos
/CCSP
pos
 lung cells.  
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Conclusion 
CD45
neg
/CCSP
pos
/SP-C
pos
 lung progenitor cells localized in BADJ show little contribution of 
airway epithelium in normal condition during growth and aging. Progenitor cells could repair 
bronchiolar epithelium by proliferating and differentiating to Clara cells after lung injury. 
Although BASCs exhibit proliferative capacity and self-renewal and are multipotency in vitro 
(10), my results could not prove that CD45
neg
/CCSP
pos
/SP-C
pos
 lung cells have a potential to 
differentiate into CD45
neg
/CCSP
neg
/SP-C
pos
 lung cells in vivo. And in Bleomycin-induced 
lung alveolar injury model, the slow and limited changes in CD45
neg
/CCSP
pos
/SP-C
pos
 lung 
cells, suggested that these cells cannot provide a major role during CD45
neg
/CCSP
neg
/SP-C
pos
 
lung cells regeneration. However, I also could not exclude from other cases that 
CD45
neg
/CCSP
neg
/SP-C
pos
 lung cells have the potential to differentiate into 
CD45
neg
/CCSP
neg
/SP-C
pos
 lung cells. So this will be my main plan for future to explore 
whether CD45
neg
/CCSP
neg
/SP-C
pos
 lung cells have the potential to differentiate into 
CD45
neg
/CCSP
neg
/SP-C
pos
 lung. 
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Figure legends 
Figure 1. Presence of CCSP and SP-C
 
positive epithelial cells in bronchioalveolar duct 
junction in mice lung. 
(A): Frozen sections of adult lung tissues were dual immunostained with anti-CCSP antibody 
and anti-CD45 antibody or anti-SP-C antibody and anti-CD45 antibody. Tissues were 
counterstained with DAPI. Left: CCSP (green), CD45 (red), ×400. Right: SP-C (green), CD45 
(red), ×200.  
(B): Adult lung tissues embedded in paraffin were dual immunostained with anti-CCSP 
antibody and anti-SP-C antibody. Right: top CCSP (red), middle SP-C (green), bottom DAPI 
(blue). Left: Double positive epithelial cells for CCSP and SP-C (yellow rectangle) in BADJ, 
×400. 
Figure 2. Presence of Sca-1-positive cells in mice lung. 
(A): CCSP
pos
/SP-C
pos
/Sca-1
pos 
lung cells in the BADJ. Immunofluorescence staining of lung 
frozen sections were performed with anti-CCSP (red), anti-SP-C (green), and anti-Sca-1 
(blue) antibodies. Right: top CCSP, middle SP-C, bottom Sca-1. Left: Merge of the photos on 
right. Triple positive cells for CCSP
pos
/SP-C
pos
/Sca-1
pos
 (arrow) are identified in BADJ, ×400.  
(B): Flow cytometry of Sca-1 expression on CD45
neg 
single lung cells. Upper row: The data of 
flow cytometry at 6 time points during growth. Bottom row: Quantitative data of 
CD45
neg
/Sca-1
pos 
cells. Data represent mean ±  SD for 3-4 samples from separate 
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experiments. *p < 0.05 
Figure 3. Changes of CD45
neg
/CCSP
pos
/SP-C
pos 
lung progenitor cells during development, 
growth and aging. 
(A): Immunofluorescence of CCSP and SP-C. Dual immunostaining for CCSP (red) and SP-C 
(green)
 
were performed in the lung tissues from embryo to adult mice. Representative of 
BADJ at different time points were presented. Yellow arrows indicate double positive cells. 
×400.  
(B): Flow cytometry of CD45
neg
/CCSP
pos
/SP-C
pos
 lung progenitor cells of 8 weeks old mice. 
Single lung cells were stained with anti-CD45, anti-CCSP, and anti-SP-C antibodies. The 
percentage of CD45
neg
/CCSP
pos
/SP-C
pos
 lung progenitor cells is determined by flow cytometry. 
Left column represents isotype control and right column represents triple stained sample. 
Bottom: Lung tissues cleared of blood. 
(C): The number of total lung cells at different time points during development, growth and 
aging. Data represent mean ± SD for 4-6 samples from separate experiments. **p < 0.01. 
(D-F): Quantitative analysis of CD45
neg
/CCSP
pos
/SP-C
pos
, CD45
neg
/CCSP
pos
/SP-C
neg
 and 
CD45
neg
/CCSP
neg
/SP-C
pos 
lung cells during development and growth. Single cells from whole 
lung were triple stained with anti-CD45, anti-CCSP, and anti-SP-C antibodies and flow 
cytometirc analysis was performed. Percentages of CD45
neg
/CCSP
pos
/SP-C
pos
, 
CD45
neg
/CCSP
pos
/SP-C
neg
 and CD45
neg
/CCSP
neg
/SP-C
pos 
lung cells at different time points 
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were plotted. Data represent mean ± SD for 4-6 samples from separate experiments. *p < 
0.05. 
(G): line graphs in (D-F). 
Figure 4. Changes of CD45
neg
/CCSP
pos
/SP-C
pos
 lung progenitor cells during the process of 
naphthalene induced airway injury and repair. 
(A): AEC immunohistochemical staining of CCSP after naphthalene treatment. ×200. 
(B): Immunofluorescence of CCSP and Ki-67 after naphthalene treatment. Dual 
immunostaining for CCSP (red) and Ki-67 (green)
 
were performed in the lung tissues at 
different time points after naphthalene treatment. Representative photographs of bronchiole 
and BADJ at different time points are presented. ×400.  
(C): Immunofluorescence of CCSP and SP-C after naphthalene treatment. Dual 
immunostaining for CCSP (red) and SP-C (green)
 
were performed in the lung tissues at 
different time points after naphthalene treatment. Representative photographs of lung are 
presented. Circles indicate double positive cells of CCSP and SP-C. CCSP (red), SP-C 
(green), DAPI (blue). ×400. 
(D-F): Quantitative analysis of CD45
neg
/CCSP
pos
/SP-C
pos
, CD45
neg
/CCSP
pos
/SP-C
neg
, 
CD45
neg
/CCSP
neg
/SP-C
pos
 lung cells during naphthalene injury and regeneration. Single cells 
from whole lung were triple stained with anti-CD45, anti-CCSP, and anti-SP-C antibodies and 
flow cytometry analysis was performed. Percentages of CD45
neg
/CCSP
pos
/SP-C
pos
, 
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CD45
neg
/CCSP
pos
/SP-C
neg
, CD45
neg
/CCSP
neg
/SP-C
pos
 lung cells at different time points are 
plotted. Data represent means ± SD for 4-6 samples from separate experiments. *p < 0.05. 
(G): line graphs in (D-F). 
(H): The number of total lung cells at different time points after naphthalene treatment. Data 
represent mean ± SD for 4-6 samples from separate experiments. 
Figure 5. Changes of CD45
neg
/CCSP
pos
/SP-C
pos
 lung progenitor cells during the process of 
bleomycin induced lung injury and repair. 
(A): HE staining during bleomycin induced lung injury and repair. Images were taken at a 
magnification of ×400.  
(B): The weight change of fourteen mice over 6 weeks by bleomycin treatment, six mice were 
dead. The × means death. 
(C) AEC immunohistochemical staining of SP-C after bleomycin treatment. ×400. 
(D): Immunofluorescence of SP-C and Ki-67 after bleomycin treatment. Dual 
immunostaining for SP-C (red) and Ki-67 (green)
 
were performed in the lung tissues at 
different time points after bleomycin treatment. Representative photographs of alveoli at 
different time points and BADJ at 6 weeks are presented. Insets are fibrotic foci. ×400. 
(E): Immunofluorescence of CCSP and SP-C after bleomycin treatment. Dual 
immunostaining for CCSP and SP-C
 
were performed in the lung tissues at different time 
points after bleomycin treatment. Representative photographs of lung at different time points 
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are presented. Circles indicate the double positive cells of CCSP and SP-C.  CCSP (red), 
SP-C (green), DAPI (blue). ×400 
(F-H): Quantitative analysis of CD45
neg
/CCSP
pos
/SP-C
pos
, CD45
neg
/CCSP
pos
/SP-C
neg 
and 
CD45
neg
/CCSP
neg
/SP-C
pos
 lung cells during bleomycin injury and regeneration. Single cells 
from whole lung were triple stained with anti-CD45, anti-CCSP, and anti-SP-C antibodies and 
flow cytometry analysis was performed. Percentages of CD45
neg
/CCSP
pos
/SP-C
pos
, 
CD45
neg
/CCSP
pos
/SP-C
neg
 and CD45
neg
/CCSP
neg
/SP-C
pos
 lung cells at different time points are 
plotted. Data represent means ± SD for 4-6 samples from separate experiments. *p < 0.05. 
(I): line graphs in (F-H). 
(J): The number of total lung cells at different time points after bleomycin treatment. Data 
represent mean ± SD for 4-6 samples from separate experiments. 
(K): AEC immunohistochemical staining with CCSP for normal 8 weeks old mouse as control 
and 6 weeks after bleomycin treatment. Images were taken at a magnification of ×200. 
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